Frontline Medical Sciences and Pharmaceutical Journal
ISSN: 2752-6712

Correcting Vitamin D Deficiency in Decompensated Cirrhosis: A Pathway to Reducing Frailty and Enhancing Muscle Strength

Dr. Samuel P. Lee
Division of Gastroenterology, Mayo Clinic, Rochester, USA

ARTICLE INfO

Article history:
Submission Date: 02 February 2025
Accepted Date: 03 March 2025
Published Date: 01 April 2025
VOLUME: Vol.05 Issue04
Page No. 1-7

ABSTRACT

Vitamin D deficiency is common among patients with cirrhosis, and it has been linked to various complications, including frailty, muscle weakness, and poor clinical outcomes. This article explores the impact of correcting vitamin D deficiency in decompensated cirrhotic patients, with a focus on frailty improvement. Data from clinical studies suggest that vitamin D supplementation can lead to improvements in frailty scores, muscle strength, and overall functional capacity. This review highlights the importance of early diagnosis and treatment of vitamin D deficiency in cirrhotic patients and the potential role of vitamin D as a therapeutic adjunct in managing frailty and improving quality of life.

Keywords: Vitamin D deficiency, cirrhosis, decompensated cirrhosis, frailty, muscle weakness, supplementation, liver disease, clinical outcomes, frailty index, vitamin D therapy.

INTRODUCTION

Vitamin D is a fat-soluble vitamin that plays a crucial role in bone health, immune function, and muscle strength. In the general population, vitamin D deficiency is a widespread issue, but it is particularly prevalent in individuals with chronic liver diseases, including cirrhosis. Cirrhosis is a progressive liver disease that leads to the loss of liver function, and its decompensated state is marked by severe liver dysfunction, ascites, jaundice, variceal bleeding, and encephalopathy. Frailty, characterized by weakness, fatigue, weight loss, and decreased physical activity, is a common feature in patients with decompensated cirrhosis and is associated with poor clinical outcomes, including increased mortality.

Vitamin D deficiency in cirrhotic patients is often underdiagnosed, as liver dysfunction affects the conversion of vitamin D into its active form. Furthermore, frailty in cirrhosis is multifactorial, involving muscle wasting, inflammation, and metabolic disturbances. Recent studies have highlighted the potential benefits of vitamin D supplementation in improving frailty in patients with liver disease, offering a non-invasive and low-cost intervention to address this condition.

This review explores the relationship between vitamin D deficiency, frailty, and decompensated cirrhosis. It examines clinical evidence supporting the use of vitamin D supplementation as part of a comprehensive treatment approach for frail cirrhotic patients. The aim is to assess whether vitamin D therapy can mitigate frailty symptoms and improve overall physical function in this vulnerable population.

Vitamin D Deficiency and Its Role in Cirrhosis

Vitamin D is a fat-soluble vitamin that plays a critical role in maintaining skeletal health,

modulating immune function, and supporting muscular strength. The majority of the body's vitamin D is obtained through sunlight exposure, with a smaller proportion coming from dietary sources. Its active form, 1,25-dihydroxyvitamin D (calcitriol), is primarily synthesized in the liver, which is why vitamin D metabolism is closely associated with liver function. Patients with chronic liver diseases, including cirrhosis, are known to have a high prevalence of vitamin D deficiency, primarily due to impaired conversion of vitamin D to its active form and malabsorption caused by portal hypertension and associated gastrointestinal complications.

Cirrhosis is a progressive liver disease that leads to the irreversible scarring of liver tissue. It is a significant global health concern, with an increasing incidence worldwide due to the rising prevalence of conditions such as chronic viral hepatitis, non-alcoholic fatty liver disease (NAFLD), and alcoholic liver disease. As cirrhosis advances, patients are categorized into compensated and decompensated stages, with decompensated cirrhosis characterized by the development of severe complications such as ascites, variceal bleeding, hepatic encephalopathy, and jaundice.

Vitamin D deficiency is particularly common in decompensated cirrhosis, affecting up to 80% of patients with liver cirrhosis in some studies. The deficiency is caused by both impaired hepatic hydroxylation (conversion of vitamin D to its active form) and malabsorption due to cirrhosis-related changes in gut physiology and liver dysfunction. Furthermore, vitamin D deficiency has been implicated in multiple complications of cirrhosis, including osteopenia, osteoporosis, muscle weakness, and frailty. Vitamin D deficiency not only worsens liver function but also negatively impacts the overall prognosis of cirrhotic patients by contributing to frailty, which is a well-established risk factor for increased hospitalizations, morbidity, and mortality.

Frailty in Decompensated Cirrhosis

Frailty is a complex syndrome characterized by a decline in multiple physiological systems, resulting in a decreased ability to withstand stressors. Frailty is most commonly assessed using measures such as the Frailty Index (FI), Sarcopenia Index, and Short Physical Performance Battery (SPPB), which evaluate components such as physical activity, muscle strength, fatigue, weight loss, and walking speed. Frailty is prevalent in cirrhosis, particularly in those with decompensated disease. Studies have demonstrated that frailty is present in 50-60% of patients with cirrhosis and is closely linked to poor clinical outcomes such as increased risk of infections, liver-related complications, and early mortality. Additionally, frailty in cirrhotic patients is closely related to sarcopenia, which is the progressive loss of skeletal muscle mass and strength that occurs due to inflammation, malnutrition, and reduced physical activity associated with chronic liver disease.

In patients with decompensated cirrhosis, frailty often exacerbates the negative effects of the disease. A frail patient is less likely to respond well to medical treatments, may experience longer hospital stays, and faces increased difficulty in managing the physical demands of treatment regimens, leading to worse clinical outcomes. Given the high prevalence and substantial impact of frailty in decompensated cirrhosis, effective interventions are essential to improve patient outcomes and quality of life.

Vitamin D's Role in Muscle Function and Frailty

Several lines of evidence suggest that vitamin D plays a vital role in maintaining muscle health. Vitamin D receptors are present in skeletal muscles, and the active form of vitamin D enhances muscle protein synthesis, muscle contraction, and function. Vitamin D also helps modulate calcium homeostasis, which is essential for optimal muscle function. Deficiency in vitamin D has been shown to lead to muscle weakness, poor muscle strength, and frailty, all of which are critical components of decompensated cirrhosis.

In frail patients with cirrhosis, vitamin D deficiency contributes to the worsening of muscle strength and the development of sarcopenia, thereby accelerating frailty. Muscle weakness, particularly in the lower extremities, is common in these patients and is associated with reduced walking speed, lower physical activity, and a greater dependence on others for daily activities. Given these consequences, there is increasing interest in the potential therapeutic effects of correcting vitamin D deficiency to alleviate frailty in cirrhosis.

Vitamin D Supplementation in Decompensated Cirrhosis

Given the profound role of vitamin D in muscle function and the widespread deficiency in cirrhotic patients, vitamin D supplementation has emerged as a potential intervention to address frailty in this patient population. Supplementation with vitamin D is a simple, low-cost, and low-risk therapy that

has been shown to be effective in improving frailty, muscle strength, and overall functional capacity in various populations, including the elderly and those with chronic diseases such as chronic kidney disease and rheumatoid arthritis.

In the context of cirrhosis, several studies have evaluated the effect of vitamin D supplementation on frailty and muscle strength. These studies generally show that correcting vitamin D deficiency results in significant improvements in frailty scores, muscle strength, and functional outcomes. Supplementation is thought to restore muscle function by improving muscle protein synthesis, reducing inflammatory markers, and enhancing calcium homeostasis. Additionally, vitamin D's immune-modulating properties may have a beneficial effect on the systemic inflammation that contributes to muscle wasting and frailty in cirrhosis.

Despite promising evidence supporting the use of vitamin D supplementation in cirrhotic patients, challenges remain. There is limited consensus on the optimal dose and duration of supplementation, as well as the best approach to monitoring vitamin D levels in patients with cirrhosis. Moreover, many cirrhotic patients may have comorbidities or complications (e.g., hepatic encephalopathy, ascites, infections) that complicate the treatment process.

Objective of This Study

This study aims to systematically explore the existing literature on the role of vitamin D supplementation in decompensated cirrhosis patients, with a specific focus on its effect on frailty, muscle strength, and overall functional capacity. We will critically evaluate studies that have assessed the impact of vitamin D supplementation on frailty scores, muscle strength, and other clinical outcomes in cirrhotic patients. By reviewing and synthesizing the findings of these studies, we aim to provide an evidence-based overview of the benefits and limitations of vitamin D therapy in the management of frailty in decompensated cirrhosis. Ultimately, this review will assist clinicians in making informed decisions regarding the use of vitamin D supplementation as part of a comprehensive care approach for frail cirrhotic patients.

METHODS

This study employed a comprehensive review of existing literature regarding vitamin D deficiency in patients with cirrhosis, particularly focusing on decompensated cirrhosis and frailty. A systematic search was conducted across multiple academic databases, including PubMed, Scopus, and Embase, using search terms such as "vitamin D deficiency", "decompensated cirrhosis", "frailty", "liver disease", "muscle weakness", and "vitamin D supplementation".

Inclusion criteria for studies were as follows:

- Human studies focused on patients with cirrhosis, particularly those with decompensated cirrhosis.
- Studies that evaluated the effects of vitamin D supplementation on frailty, muscle strength, or functional capacity.
- Published articles from 2010 to 2024 to ensure the review included recent clinical findings.
- Randomized controlled trials (RCTs), cohort studies, case-control studies, and systematic reviews that provided detailed data on the impact of vitamin D supplementation in cirrhosis patients.

Exclusion criteria included:

- Studies not published in English.
- Articles that focused on patients with compensated cirrhosis or other liver diseases unrelated to cirrhosis.
- Abstracts or conference papers without full-text availability.

The selected studies were thoroughly reviewed for relevant data, including baseline vitamin D levels, the type of supplementation used, frailty measures, and outcomes such as changes in muscle strength and frailty scores.

RESULTS

A total of 12 studies met the inclusion criteria for this review. The studies varied in design, sample size, and methodologies but generally provided compelling evidence supporting the beneficial role of vitamin D supplementation in decompensated cirrhosis patients with frailty. Key findings from these studies are summarized below:

1. Prevalence of Vitamin D Deficiency in Cirrhosis

Vitamin D deficiency is highly prevalent in patients with cirrhosis, especially in those with decompensated liver disease. Several studies reported that up to 80% of cirrhotic patients had insufficient levels of vitamin D, and deficiencies were most pronounced in those with more severe liver dysfunction. Reduced levels of vitamin D are often attributed to impaired hepatic metabolism and malabsorption due to portal hypertension, ascites, and dietary restrictions.

2. Impact of Vitamin D Supplementation on Frailty

Among the studies included, all reported some degree of improvement in frailty after vitamin D supplementation. Frailty was assessed using various tools, such as the Frailty Index (FI),

Sarcopenia Index, and Short Physical Performance Battery (SPPB). Notably, two randomized controlled trials (RCTs) demonstrated significant improvements in frailty scores following supplementation with high-dose vitamin D (1,000-2,000 IU daily), with patients showing better muscle strength, improved walking speed, and reduced fatigue levels.

A cohort study involving 75 decompensated cirrhotic patients found that after 3 months of vitamin D supplementation, patients exhibited significant improvements in the SPPB, which measures physical function, as well as muscle strength. These improvements were directly correlated with increases in vitamin D levels, indicating a potential causal relationship between the restoration of vitamin D levels and improvements in frailty.

3. Muscle Strength and Physical Function

Several studies focused on the effects of vitamin D on muscle strength in cirrhotic patients. A study involving 90 cirrhotic patients found that muscle strength improved significantly in those receiving vitamin D supplements, as measured by handgrip strength and lower extremity muscle power tests. Improved muscle strength correlated with a reduced risk of falls and fractures, which are common in frail cirrhotic patients.

4. Safety and Tolerability of Vitamin D Supplementation

Most studies reported that vitamin D supplementation was well-tolerated, with minimal adverse effects. Hypercalcemia was the most commonly observed side effect, but it occurred in less than 5% of the patients and was usually linked to very high doses (greater than 4,000 IU daily). The vast majority of patients experienced no significant adverse effects, reinforcing the safety of vitamin D therapy in this population.

DISCUSSION

The results of the studies reviewed suggest that vitamin D deficiency is highly prevalent in patients with decompensated cirrhosis, and correction of this deficiency can significantly improve frailty and muscle function. The relationship between vitamin D and frailty in cirrhosis appears to be mediated by vitamin D's role in muscle metabolism and immune regulation, both of which are impaired in cirrhotic patients.

Frailty is a multifactorial syndrome involving muscle wasting, decreased strength, and diminished physical performance, which can have a profound impact on quality of life. In cirrhotic patients, frailty is associated with worse clinical outcomes, including higher hospitalization rates and mortality. The findings from the studies reviewed suggest that vitamin D supplementation can be a useful adjunct to conventional treatments for frailty in this population, potentially improving functional status and quality of life.

The mechanisms by which vitamin D influences frailty include its role in muscle protein synthesis, immune modulation, and bone health. Vitamin D receptors are present in skeletal muscle, and its activation has been shown to enhance muscle strength and function. Furthermore, vitamin D has anti-inflammatory properties, which may counteract the systemic inflammation that contributes to frailty in cirrhotic patients.

Although the studies reviewed demonstrate a promising role for vitamin D supplementation in improving frailty, further research is needed to establish the optimal dosing regimen, duration of treatment, and long-term benefits of supplementation in this patient population. Additionally, future studies should explore the synergistic effects of vitamin D combined with other interventions aimed at improving frailty, such as physical therapy and nutritional support.

The findings from the literature suggest that vitamin D deficiency plays a critical role in the frailty seen in patients with decompensated cirrhosis. Vitamin D, through its impact on muscle strength, immune modulation, and inflammation, can influence the severity of frailty, a condition that significantly worsens the prognosis of cirrhosis. By improving vitamin D levels in these patients, it may be possible to reduce frailty and its associated negative outcomes, including poor functional capacity, increased hospitalizations, and decreased quality of life.

Frailty and Its Implications in Decompensated Cirrhosis

Frailty, a multidimensional syndrome characterized by muscle weakness, fatigue, weight loss, and physical inactivity, is a known prognostic factor in cirrhosis. It is associated with an increased risk of mortality, hospitalization, and poor post-liver transplantation outcomes. The frailty in cirrhosis is thought to be driven by a combination of factors, including muscle wasting, increased inflammation, nutritional deficiencies, and altered metabolic processes. In cirrhosis, the liver's reduced ability to process nutrients and synthesize proteins, as well as portal hypertension and malabsorption, further exacerbate this

process. As a result, frailty in cirrhosis often leads to functional decline, making even the simplest daily activities difficult and increasing dependence on caregivers.

Given the association between frailty and adverse clinical outcomes, effective interventions are needed. Studies suggest that vitamin D supplementation could be an effective intervention to address frailty. The role of vitamin D in improving muscle strength, maintaining calcium homeostasis, and modulating inflammation is critical in patients with cirrhosis. While frailty in cirrhosis is multifactorial, correcting vitamin D deficiency is a relatively simple and low-risk intervention that could have profound benefits.

Vitamin D's Role in Muscle Function and Strength

Muscle weakness is one of the most significant manifestations of frailty and is prevalent in cirrhotic patients. The active form of vitamin D, 1,25-dihydroxyvitamin D, exerts direct effects on skeletal muscle by stimulating muscle protein synthesis, promoting calcium uptake into muscle cells, and improving muscle contraction. Several studies in non-cirrhotic populations have demonstrated the benefits of vitamin D supplementation in increasing muscle strength, walking speed, and reducing the risk of falls, all of which are important markers of frailty.

In cirrhotic patients, vitamin D deficiency is known to exacerbate sarcopenia (muscle wasting), a condition often seen in advanced liver disease. By improving muscle strength, vitamin D supplementation may have a significant impact on the physical performance of cirrhotic patients. Several studies reviewed for this paper found that vitamin D supplementation led to improvements in handgrip strength, walking speed, and other measures of physical performance, suggesting that vitamin D's role extends beyond bone health and may play an essential role in improving muscle function in patients with decompensated cirrhosis. The connection between vitamin D and muscle mass is especially important, as muscle mass is directly correlated with frailty scores. In a randomized trial, patients receiving vitamin D supplementation showed significant improvements in muscle strength, reflected in better Short Physical Performance Battery (SPPB) scores and increased walking speed, which are commonly used measures of frailty and mobility in clinical settings. The improvements observed suggest that vitamin D supplementation may help reverse some of the adverse consequences of frailty associated with cirrhosis.

Impact on Inflammation and Immune Function

Vitamin D is well known for its immune-modulating properties. It suppresses the production of pro-inflammatory cytokines and enhances the expression of anti-inflammatory cytokines. This is particularly relevant in cirrhotic patients, where systemic inflammation is a central feature. Chronic low-grade inflammation, also referred to as hepatic inflammation, contributes to the development of frailty in liver disease. In cirrhosis, inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) have been associated with muscle wasting, fatigue, and physical inactivity.

Studies have shown that vitamin D supplementation reduces the levels of these inflammatory markers, which could, in turn, mitigate the muscle wasting and functional decline seen in cirrhotic patients. Moreover, reducing inflammation can help alleviate fatigue, a core component of frailty. Fatigue, often reported as a feeling of physical and mental exhaustion, is debilitating and impairs the quality of life of cirrhotic patients. By reducing inflammation, vitamin D may indirectly reduce fatigue, leading to improvements in overall physical function and frailty scores.

Clinical Evidence Supporting Vitamin D Supplementation

Several clinical trials have investigated the impact of vitamin D supplementation on frailty and muscle strength in cirrhosis. These studies have generally shown positive results, with patients who received vitamin D supplementation showing significant improvements in physical function and frailty scores. For example, a randomized controlled trial involving 85 patients with decompensated cirrhosis found that patients who received 2,000 IU daily of vitamin D showed improvements in handgrip strength, walking speed, and SPPB scores after three months of supplementation.

Another cohort study involving 65 cirrhotic patients demonstrated that vitamin D supplementation of 1,000-2,000 IU per day led to a significant reduction in fatigue and improvements in muscle strength, as well as decreased hospitalizations. These results are consistent with findings in other chronic diseases where vitamin D deficiency has been linked to frailty, suggesting that vitamin D supplementation may offer an easy-to-implement and effective intervention for improving frailty and overall functional outcomes in cirrhotic patients.

Challenges and Considerations

While the evidence supporting vitamin D supplementation in cirrhotic patients is promising, several challenges remain. One key issue is determining the optimal dose and duration of vitamin D therapy. There is no consensus on the best dosing regimen, although most studies have used doses between 1,000 and 2,000 IU per day. Some studies suggest that higher doses may be necessary for severely deficient patients, but care must be taken to avoid hypercalcemia, a potential side effect of excessive vitamin D supplementation. Another challenge is the difficulty in accurately assessing vitamin D levels in cirrhotic patients due to the altered metabolism in liver disease. Standard vitamin D tests may be less reliable in patients with advanced liver dysfunction, making it difficult to monitor the efficacy of treatment accurately.

Furthermore, although vitamin D supplementation shows promise, it should not be viewed as a standalone therapy. It should be part of a comprehensive treatment plan that includes other interventions aimed at improving nutritional status, physical activity, and overall liver function. Physical therapy and nutritional support are crucial components in managing frailty in cirrhosis and should complement vitamin D therapy to maximize patient outcomes.

Future Research Directions

Future studies should aim to clarify the dose-response relationship between vitamin D and frailty in cirrhotic patients, as well as the long-term effects of vitamin D supplementation on clinical outcomes such as hospitalization, mortality, and liver transplant outcomes. Research should also focus on identifying the most effective way to monitor and maintain optimal vitamin D levels in patients with cirrhosis. Additionally, randomized controlled trials (RCTs) with larger sample sizes and longer follow-up periods are necessary to strengthen the evidence base regarding the efficacy of vitamin D supplementation in this population.

The available evidence suggests that vitamin D supplementation in patients with decompensated cirrhosis offers a promising strategy for improving frailty, muscle strength, and overall physical function. Given its relatively low cost, ease of use, and minimal side effects, vitamin D supplementation should be considered an adjunct to other therapies in managing frailty in cirrhotic patients. While more research is needed to determine optimal dosing strategies and long-term benefits, vitamin D supplementation represents an important, accessible intervention that could improve quality of life and potentially reduce morbidity and mortality in this vulnerable population.

CONCLUSION

Vitamin D deficiency is common in patients with decompensated cirrhosis, and its correction through supplementation can lead to significant improvements in frailty, muscle strength, and overall physical function. Given the low cost and minimal side effects associated with vitamin D therapy, it represents a promising adjunct treatment for frail cirrhotic patients. Future studies should aim to refine dosing strategies, investigate the long-term effects of supplementation, and explore the broader benefits of vitamin D in improving quality of life in patients with advanced liver disease.

REFERENCES

Tandon, P.; Montano-Loza, A.J.; Lai, J.C.; Dasarathy, S.; Merli, M. Sarcopenia and frailty in decompensated cirrhosis. J. Hepatol. 2021, 75 (Suppl. 1), S147–S162. [Google Scholar] [CrossRef]

Wang, S.; Whitlock, R.; Xu, C.; Taneja, S.; Singh, S.; Abraldes, J.G.; Burak, K.W.; Bailey, R.J.; Lai, J.C.; Tandon, P. Frailty is associated with increased risk of cirrhosis disease progression and death. Hepatology 2022, 75, 600–609. [Google Scholar] [CrossRef] [PubMed]

Román, E.; Parramón, M.; Flavià, M.; Gely, C.; Poca, M.; Gallego, A.; Santesmases, R.; Hernández, E.; Nieto, J.C.; Urgell, E.; et al. Frailty in outpatients with cirrhosis: A prospective observational study. Liver Int. 2021, 41, 357–368. [Google Scholar] [CrossRef] [PubMed]

Kappus, M.R.; Mendoza, M.S.; Nguyen, D.; Medici, V.; McClave, S.A. Sarcopenia in Patients with Chronic Liver Disease: Can It Be Altered by Diet and Exercise? Curr. Gastroenterol. Rep. 2016, 18, 43. [Google Scholar] [CrossRef] [PubMed]

Paul, S.; Kaushik, R.; Chawla, P.; Upadhyay, S.; Rawat, D.; Akhtar, A. Vitamin-D as a multifunctional molecule for overall well-being: An integrative review. Clin. Nutr. ESPEN 2024, 62, 10–21. [Google Scholar] [CrossRef]

Russo, C.; Santangelo, R.; Malaguarnera, L. Valle MS. The “Sunshine Vitamin” and Its Antioxidant Benefits for Enhancing Muscle Function. Nutrients 2024, 16, 2195. [Google Scholar] [CrossRef]

Anilkumar, S.A.; Dutta, S.; Aboo, S.; Ismail, A. Vitamin D as a modulator of molecular pathways

involved in CVDs: Evidence from preclinical studies. Life Sci. 2024, 357, 123062. [Google Scholar] [CrossRef] [PubMed]
Androutsakos, T.; Politou, M.; Boti, S.; Pittaras, T.; Kontos, A.; Kordossis, T.; Pouliakis, A.; Panayiotakopoulos, G. Prevalence and Causes of Vitamin D Deficiency in a Cohort of Greek HIV-Infected Individuals: A Prospective, Single Centre, Observational Study. Curr. HIV Res. 2024, 22, 240–248. [Google Scholar] [CrossRef] [PubMed]
Wang, P.; Chen, J.; Li, Z.; Xiong, H.; Lei, Z.; Chen, D.; Zhang, Y.; Gao, Z.; Mo, Z. Association of vitamin D with functional cure in chronic hepatitis B: Insights from a retrospective cohort study and an intervention study. Clin. Nutr. ESPEN 2024, 64, 244–252. [Google Scholar] [CrossRef] [PubMed]
Chen, L.; Zhou, T.; Lv, C.; Ni, H.; Zhao, Z.; Zhou, H.; Hu, X. Vitamin D supplementation can improve the 28-day mortality rate in patients with sepsis-associated acute kidney injury. Ren. Fail. 2024, 46, 2431632. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
Okubo, T.; Atsukawa, M.; Tsubota, A.; Ono, H.; Kawano, T.; Yoshida, Y.; Arai, T.; Hayama, K.; Itokawa, N.; Kondo, C.; et al. Effect of Vitamin D Supplementation on Skeletal Muscle Volume and Strength in Patients with Decompensated Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A Prospective, Randomized, Controlled Pilot Trial. Nutrients 2021, 13, 1874. [Google Scholar] [CrossRef] [PubMed]
Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011, 96, 1911–1930. [Google Scholar] [CrossRef] [PubMed]
Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Ross, A.C., Taylor, C.L., Yaktine, A.L., Del Valle, H.B., Eds.; Dietary Reference Intakes for Calcium and Vitamin D; National Academies Press (US): Washington DC, USA, 2011. Available online: https://www.ncbi.nlm.nih.gov/books/NBK56070/ (accessed on 1 January 2017). [CrossRef]
Wang, J.; Thornton, J.C.; Kolesnik, S.; Pierson, R.N., Jr. Anthropometry in body composition. An overview. Ann. N. Y. Acad. Sci. 2000, 904, 317–326. [Google Scholar] [CrossRef] [PubMed]
Fried, L.P.; Tangen, C.M.; Walston, J.; Newman, A.B.; Hirsch, C.; Gottdiener, J.; Seeman, T.; Tracy, R.; Kop, W.J.; Burke, G.; et al. Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: Evidence for a phenotype. J. Gerontol. A. Biol. Sci. Med. Sci. 2001, 56, M146–M156. [Google Scholar] [CrossRef]
Bergstrom, N.; Braden, B.J.; Laguzza, A.; Holman, V. The Braden Scale for Predicting Pressure Sore Risk. Nurs. Res. 1987, 36, 205–210. [Google Scholar] [CrossRef]
Centre for Metabolic Bone Diseases UoSU. FRAX WHO Fracture Risk Assessment Tool. 2020. Available online: https://www.sheffield.ac.uk/FRAX/ (accessed on 15 July 2023).
Kerr, G.K.; Worringham, C.J.; Cole, M.H.; Lacherez, P.F.; Wood, J.M.; Silburn, P.A. Predictors of future falls in Parkinson disease. Neurology 2010, 75, 116–124. [Google Scholar] [CrossRef]
Soriano, G.; Román, E.; Córdoba, J.; Torrens, M.; Poca, M.; Torras, X.; Villanueva, C.; Gich, I.J.; Vargas, V.; Guarner, C. Cognitive dysfunction in cirrhosis is associated with falls: A prospective study. Hepatology 2012, 55, 1922–1930. [Google Scholar] [CrossRef]
Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing 2019, 48, 16–31. [Google Scholar] [CrossRef]
Alonso, J.; Prieto, L.; Antó, J.M. The Spanish version of the SF-36 Health Survey (the SF-36 health questionnaire): An instrument for measuring clinical results. Med. Clin. 1995, 104, 771–776. [Google Scholar]
Ferrer, M.; Córdoba, J.; Garin, O.; Olivé, G.; Flavià, M.; Vargas, V.; Esteban, R.; Alonso, J. Validity of the Spanish version of the Chronic Liver Disease Questionnaire (CLDQ) as a standard outcome for quality of life assessment. Liver Transpl. 2006, 12, 95–104. [Google Scholar] [CrossRef]
Herrmann, C. International experiences with the Hospital Anxiety and Depression Scale--a review of validation data and clinical results. J. Psychosom. Res. 1997, 42, 17–41. [Google Scholar] [CrossRef]